Targets › OPRM1
102 programs from 83 companies in 486 trials: 156 Phase 4, 140 Phase 2, 126 Phase 1, 64 Phase 3; Other, Psychiatry, Oncology; next expected readout Nov 2026.
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. (UniProt, P35372)
Open in Phaseline: the race on OPRM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Meri Mirceta | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Colorectal Carcinoma | Nov 2026 |
| Rush University Medical Center | Sufentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Minor Surgical Procedures With Monitored Anesthesia Care | Nov 2026 |
| Pamukkale University | remifentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Tracheal Extubation | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Universidad Nacional Autonoma de Honduras | Tramadol Hydrochloride Mu opioid receptor agonist | OPRM1 | Phase 4 | Labor Pain | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Xiangya Hospital of Central South University | Tegileridine Fumarate Injection Biased μ-opioid receptor agonist | OPRM1 | Phase 4 | Pain, Postoperative | Dec 2026 |
| M.D. Anderson Cancer Center | [18F]-4FN PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274 | Phase 4 | Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm … | Dec 2026 |
| M.D. Anderson Cancer Center | Methylnaltrexone Mu opioid receptor antagonist | OPRM1 | Phase 4 | Head and Neck Squamous Cell Carcinoma | Dec 2026 |
| Indiana University | methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Free Flap Reconstruction; Testicular Cancer | Dec 2026 |
| Inonu University | Remifentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Hemodynamic Response | Feb 2027 |
| University of Michigan | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 4 | Surgery | Feb 2027 |
| University of Michigan | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Surgery | Feb 2027 |
| Unity Health Toronto | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Spinal Surgery | Mar 2027 |
| Montefiore Medical Center | buprenorphine-naloxone Partial mu-opioid receptor agonist with naloxone opioid antagonist | OPRM1 | Phase 4 | Opioid Use Disorder | Mar 2027 |
| Tianjin Medical University General Hospital | Oliceridine Mu opioid receptor agonist | OPRM1 | Phase 4 | Chronic Postsurgical Pain | Mar 2027 |
| Nordsjaellands Hospital | Remifentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Tracheal Intubation | Apr 2027 |
| Brandon Knopp | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Pain, Postoperative | Apr 2027 |
| Anne Juul Wikkelsø | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Caesarean Section | May 2027 |
| Northwestern University | Morphine Sulfate Mu opioid receptor agonist | OPRM1 | Phase 4 | Pain, Postoperative | Jun 2027 |
| Duke University | Methadone hydrochloride Mu opioid receptor agonist | OPRM1 | Phase 4 | Cleft Palate; Pain, Postoperative | Jun 2027 |
| Columbia University | Naltrexone-Bupropion Combination Opioid receptor antagonist (naltrexone) combined with norepinephrine-dopamine reuptake inh | OPRM1, SLC6A3 | Phase 4 | Obesity | Jun 2027 |
| The Methodist Hospital Research Institute | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Anterior Cruciate Ligament Tear | Jul 2027 |
| Northwestern University | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 4 | Ventral Hernia | Sep 2027 |
| The Cleveland Clinic | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Post Operative Pain | Oct 2027 |
| Peking Union Medical College Hospital | Tegileridine μ-opioid receptor-biased agonist | OPRM1 | Phase 4 | Scoliosis; Adolescence | Oct 2027 |
| Indiana University | sufentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Free Flap Reconstruction | Nov 2027 |
| Murdoch Childrens Research Institute | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Patient-Controlled Analgesia | Dec 2027 |
| M.D. Anderson Cancer Center | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 4 | Hematopoietic and Lymphoid Cell Neoplasm | Dec 2027 |
| University Hospital, Limoges | Sufentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Laparoscopic Cholecystectomy Surgery | Jan 2028 |
| AdventHealth | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Total Knee Arthroplasty | Apr 2028 |
| Yale University | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Opioid Use Disorder | Dec 2028 |
| Currax Pharmaceuticals | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Obesity | Jan 2029 |
| OHSU Knight Cancer Institute | Methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | Head and Neck Carcinoma | Jul 2029 |
| The Royal's Institute of Mental Health Research | Contrave Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop | OPRM1, SLC6A2, SLC6A3 | Phase 4 | Obesity | – |
| Endeavor Health | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 4 | EKG-QT Prolongation | – |
| Nova Scotia Health Authority | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 4 | Pain, Postoperative | – |
| Hospital Central do Funchal | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Analgesia Obstetrical | – |
| The Metis Foundation | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Wound of Skin | – |
| First Affiliated Hospital, Sun Yat-Sen University | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Patients Undergoing Major Laparoscopic Abdominal Surgery | – |
| Medical University of Silesia | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Analgesics, Opioid | – |
| University of California, San Diego | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Hepatic Resection | – |
| Universiti Sains Malaysia | Morphine Mu opioid receptor agonist | OPRM1 | Phase 4 | Effect of Drug | – |
| Khon Kaen University | Morphine Sulfate Mu opioid receptor agonist | OPRM1 | Phase 4 | Pruritus Caused by Drug | – |
| Middle Tennessee Research Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Low Back Pain | – |
| University of Colorado, Denver | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Harm Reduction | – |
| Friends Research Institute, Inc. | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| Pouya Azar | Naloxone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| Shiyou Wei | Oliceridine (TRV130) Mu opioid receptor agonist | OPRM1 | Phase 4 | Cough | – |
| Centre Hospitalier Universitaire, Amiens | Sufentanil Mu opioid receptor agonist | OPRM1 | Phase 4 | Chronic Postsurgical Pain | – |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Tegileridine Fumarate μ-opioid receptor agonist | OPRM1 | Phase 4 | Postoperative Pain | – |
| Endeavor Health | methadone Mu opioid receptor agonist | OPRM1 | Phase 4 | EKG-QT Prolongation; Quality of Recovery Scores | – |
| Ensysce Biosciences | Oxycodone (PF614) Mu opioid receptor agonist | OPRM1 | Phase 3 | Postoperative Pain, Acute; Pharmacokinetics; Laparoscopic Hysterectomy; Liquid Oxycodone … | Nov 2026 |
| University of Maryland, Baltimore | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Opioid Use Disorder; Pain | Nov 2026 |
| Medical University of South Carolina | Methadone Hydrochloride Mu opioid receptor agonist | OPRM1 | Phase 3 | Post Operative Pain | Dec 2026 |
| Indiana University | Morphine Mu opioid receptor agonist | OPRM1 | Phase 3 | Testicular Cancer | Dec 2026 |
| Adneuris Therapeutics | Cebranopadol Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist | OPRL1, OPRK1, OPRD1, OPRM1 | Phase 3 | Pain; Chronic Pain | Jan 2027 |
| University Hospital, Clermont-Ferrand | Sufentanil Mu opioid receptor agonist | OPRM1 | Phase 3 | Pain Management | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | Methadone Mu opioid receptor agonist | OPRM1 | Phase 3 | Spinal Surgery | Jun 2027 |
| University of Toronto | Morphine Mu opioid receptor agonist | OPRM1 | Phase 3 | Arthroplasties, Knee Replacement | Jul 2027 |
| Trevi Therapeutics | Nalbuphine Opioid receptors; mu/kappa/delta agonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute … | Aug 2027 |
| Hans Bahlmann | Morphine Mu opioid receptor agonist | OPRM1 | Phase 3 | Other Specified Disorders of Kidney and Ureter | Oct 2027 |
| The First Hospital of Jilin University | Tegileridine (tegileridine fumarate injection, IV) Biased μ-opioid receptor agonist | OPRM1 | Phase 3 | Pain Management | Oct 2027 |
| Jason Sperry | Fentanyl Citrate Mu opioid receptor agonist | OPRM1 | Phase 3 | Traumatic Injury | Jul 2028 |
| University Hospital, Grenoble | Sufentanil Mu opioid receptor agonist | OPRM1 | Phase 3 | Brain-dead Organ Donors | Sep 2028 |
| Memorial Sloan Kettering Cancer Center | alvimopan Mu opioid receptor antagonist | OPRM1 | Phase 3 | Bladder Cancer | Nov 2028 |
| Senthil Sadhasivam | Methadone Mu opioid receptor agonist | OPRM1 | Phase 3 | Idiopathic Scoliosis | Jan 2029 |
| Senthil Sadhasivam | Methadone-based ERAS Opioid analgesic (mu receptor agonist) administered intraoperatively and postoperatively f | OPRM1 | Phase 3 | Pediatric Cardiac Surgery | Jan 2029 |
| Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program | Methadone Mu opioid receptor agonist | OPRM1 | Phase 3 | Neonatal Opioid Withdrawal Syndrome | – |
| Brugmann University Hospital | Methadone Hydrochloride Mu opioid receptor agonist | OPRM1 | Phase 3 | Orthopedic Surgery | – |
| Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program | Morphine Mu opioid receptor agonist | OPRM1 | Phase 3 | Neonatal Opioid Withdrawal Syndrome | – |
| AgelessRx | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug … | – |
| Murdoch Childrens Research Institute | Remifentanil Mu opioid receptor agonist | OPRM1 | Phase 3 | Anesthesia | – |
| Alkermes | Samidorphan Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist | OPRM1, OPRK1, OPRD1 | Phase 3 | Schizophrenia | – |
| Avenue Therapeutics | Tramadol (AVE-901) Mu opioid receptor agonist | OPRM1 | Phase 3 | Pain Management; Shoulder Arthropathy; Postoperative Pain; Post-surgical Pain … | – |
| Wayne State University | Morphine Mu opioid receptor agonist | OPRM1 | Phase 2 | Opioid Abuse | Dec 2026 |
| University of Iowa | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 2 | Laparotomy | Dec 2026 |
| Medical University of Lublin | Naltrexone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Vulvodynia | Dec 2026 |
| New York State Psychiatric Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Jan 2027 |
| University of Maryland, Baltimore | Methadone Mu opioid receptor agonist | OPRM1 | Phase 2 | Opioid Use Disorder | Jun 2027 |
| University of British Columbia | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Dec 2027 |
| KK Women's and Children's Hospital | Meperidine Mu opioid receptor agonist | OPRM1 | Phase 2 | Depression, Postpartum | Dec 2027 |
| KK Women's and Children's Hospital | Morphine Mu opioid receptor agonist | OPRM1 | Phase 2 | Respiratory Depression; Pain | Dec 2027 |
| KK Women's and Children's Hospital | Remifentanil Mu opioid receptor agonist | OPRM1 | Phase 2 | Depression, Postpartum | Dec 2027 |
| University of British Columbia | methadone Mu opioid receptor agonist | OPRM1 | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | – |
| ReacX Pharmaceuticals | Nalmefene Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist | OPRM1, OPRD1, OPRK1 | Phase 1 | Opioid Abuse and Addiction; Behavioural Addiction | Dec 2026 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Hydromorphone Mu opioid receptor agonist | OPRM1 | Phase 1 | Acute Chest Pain | Dec 2026 |
| University Hospital, Grenoble | Morphine Mu opioid receptor agonist | OPRM1 | Phase 1 | Chronic Obstructive Pulmonary Disease | Jun 2027 |
| Boulder Care | Buprenorphine Mu opioid receptor agonist; Kappa opioid receptor agonist | OPRM1, OPRK1 | Phase 1 | Opioid Use Disorder; Postoperative Pain; Pain, Postoperative; Acute Postoperative Pain … | Aug 2027 |
| University of Pennsylvania | [11C]Carfentanil Mu opioid receptor agonist radiotracer | OPRM1 | Phase 1 | Healthy | Sep 2027 |
| M.D. Anderson Cancer Center | Loperamide Mu opioid receptor agonist | OPRM1 | Phase 1 | Colitis | Dec 2027 |
| Ashish P Thakrar, MD MS | Methadone hydrochloride Mu opioid receptor agonist | OPRM1 | Phase 1 | Opioid Use Disorder (OUD) | Dec 2027 |
| Shionogi | Naldemedine Mu opioid receptor antagonist | OPRM1 | Phase 1 | Opioid-Induced Constipation (OIC) | Jun 2028 |
| John Kirkwood | Axelopran Peripherally restricted mu-opioid receptor antagonist (PAMORA) | OPRM1 | Phase 1 | Unresectable Cutaneous Melanoma | Jul 2028 |
| Akyso Therapeutics | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 1 | Opioid Use Disorder | Oct 2029 |
| Haiphong University of Medicine and Pharmacy | DW-1021 Fixed-dose combination of nonsteroidal anti-inflammatory drug and opioid analgesic | PTGS1, PTGS2, OPRM1 | Phase 1 | Healthy Volunteer | – |
| Lee's Pharmaceutical | Fentanyl Mu opioid receptor agonist | OPRM1 | Phase 1 | Cancer; Vaginal Delivery; Spinal Anesthesia Duration; Effect of Drug … | – |
| Inventage Lab. | IVL3004 Opioid receptor antagonist (long-acting injection) | OPRM1 | Phase 1 | Opioid Dependence | – |
| Inventage Lab. | IVL4002 Opioid receptor antagonist (long-acting injection) | OPRM1 | Phase 1 | Opioid Dependence | – |
| Minia University | Morphine Mu opioid receptor agonist | OPRM1 | Phase 1 | Post-operative Pain Management | – |
Opioid Use Disorder (28) Pain, Postoperative (8) Obesity (6) Acute Myeloid Leukemia (6) Opioid-use Disorder (5) Alcohol Use Disorder (5) Analgesia (5) Pain (4) Bladder Cancer (4) Opioid Use Disorder (OUD) (4) Surgery (4) Prostate Cancer (4)
small molecule (94), mixed (5)
M.D. Anderson Cancer Center (4) KK Women's and Children's Hospital (3) Indiana University (3) Memorial Sloan Kettering Cancer Center (2) Northwestern University (2) Endeavor Health (2) University of British Columbia (2) Murdoch Childrens Research Institute (2) University of Michigan (2) University Hospital, Grenoble (2) University of Maryland, Baltimore (2) Inventage Lab. (2) Senthil Sadhasivam (2) University of Pennsylvania (2) Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program (2) Columbia University (1) Hospital Central do Funchal (1) The Metis Foundation (1) Middle Tennessee Research Institute (1) Meri Mirceta (1)
OPRK1 (17) OPRD1 (16) HTR2A (3) CHRNB2 (3) CHRNA4 (3) SLC6A3 (2) AGTR1 (2) PDCD1 (2) SLC6A2 (2) GLP1R (2) Tubulin (2) SLC6A4 (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.